ACIP Updates Recommendations for US Adult Immunization Schedule
The ACIP and CDC have approved and released 2019 recommendations for the adult immunization schedule in the US.
Infections
INFECTIONS
FEATURE ARTICLE
LATEST NEWS
Dermatologists Can Play Important Role in the Prevention of Herpes Zoster Infection
Dermatologists have not traditionally played a systematic role in recommending and administering immunizations.
Ready-to-Use, Room Temp Stable, Premixed Vancomycin Injection Gets FDA Approval
Xellia announced that the Food and Drug Administration (FDA) has approved its Premixed Vancomycin Injection in a Ready-to-Use bag.
Risk for MRSA Reduced With Postdischarge Decolonization
For patients colonized with methicillin-resistant Staphylococcus aureus (MRSA), postdischarge MRSA decolonization is associated with a reduced risk for infection.
FDA Issues Complete Response Letter Rejecting Iclaprim Approval for ABSSSI
The NDA included data from the Phase 3 REVIVE-1 and REVIVE-2 trials.
Dermatology, Infectious Disease Collaboration May Optimize Detection of Sexually Transmitted Infections
Over the study period, significant increases in the number of screening tests, as well as the ratio between the tests and hospital admissions, was observed.
Progress Made in Developing New Antibacterial Agents
Although there has been progress in the development of new antibacterial drugs, most of the recently approved agents have been modifications of existing chemical classes of antibiotics.
Nuzyra Now Available in IV, Oral Forms for CABP, ABSSSI
Nuzyra, an aminomethylcycline (related to tetracycline antibiotics), is designed to overcome tetracycline resistance and has broad-spectrum activity against Gram-positive, Gram-negative and atypical bacteria, and other drug-resistant strains.
Trends in US Herpes Zoster Hospitalizations From 2001 to 2015
The 2007 and 2008 shingles and varicella vaccination recommendations may have contributed to the declining herpes zoster hospitalization rates in some groups.
Omadacycline Noninferior to Moxifloxacin in CABP Study, Linezolid in ABSSSI Study
Omadacycline is noninferior to moxifloxacin for community-acquired bacterial pneumonia and noninferior to linezolid for acute bacterial skin infections.
CDC Examines Safety of Recombinant Zoster Vaccine
During the first eight months of recombinant zoster vaccine (RZV) use, there were reports of 4,381 adverse events, 3 percent of which were serious.
Want to read more?
Please login or register first to view this content.
Next post in Infections
